Behnaz Rahmani
Overview
Explore the profile of Behnaz Rahmani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kheirandish M, Rahmani B, Zarei Jaliani H, Barkhordari F, Mazlomi M, Davami F
Mol Biol Rep
. 2023 May;
50(7):5889-5899.
PMID: 37244887
Background: Conventional methods applied to develop recombinant CHO (rCHO) cell line as a predominant host for mammalian protein expression are limited to random integration approaches, which can prolong the process...
2.
Rahmani B, Kheirandish M, Ghanbari S, Raz A, Shamsi F, Davami F
Sci Rep
. 2023 Feb;
13(1):3116.
PMID: 36813818
CRISPR-mediated integration could be used to develop the recombinant CHO (rCHO) cells by knock-in into the hotspot loci. However, low HDR efficiency besides the complex donor design is the main...
3.
Amiri S, Adibzadeh S, Ghanbari S, Rahmani B, Kheirandish M, Farokhi-Fard A, et al.
Biotechnol Bioeng
. 2023 Jan;
120(4):865-902.
PMID: 36597180
For industrial production of recombinant protein biopharmaceuticals, Chinese hamster ovary (CHO) cells represent the most widely adopted host cell system, owing to their capacity to produce high-quality biologics with human-like...
4.
Kheirandish M, Zarei Jaliani H, Rahmani B, Nikukar H
Toxicon
. 2022 Nov;
221:106966.
PMID: 36402121
No abstract available.
5.
Rahmani B, Astani A, Zarei Jaliani H, Kheirandish M, Mosaddegh A
Iran J Basic Med Sci
. 2021 Oct;
24(6):851-855.
PMID: 34630963
Objectives: has become a major clinical concern due to the growing prevalence of multi-drug resistant (MDR) strains. Enzybioticts are peptidoglycan hydrolases that are recently introduced as an alternative agent to...
6.
Kheirandish M, Zarei Jaliani H, Rahmani B, Nikukar H
Toxicon
. 2019 Apr;
164:82-86.
PMID: 30991063
Conventional drug delivery systems have many limitations including cytotoxicity and affecting non-specific cells. Cell-targeting peptides (CTPs) as a potential class of targeting moiety have some advantages over previous targeting moieties...